RUTH FELDMAN: Open Payments
NPI 1255930624 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,055 in 98 payments from 15 companies in 2025. Trend: 2023 $1,503 · 2024 $2,153 · 2025 $2,055
Food & beverage: $2,055
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $404 |
| Lundbeck LLC | 20 | $341 |
| Axsome Therapeutics, Inc. | 13 | $306 |
| Neurocrine BioSciences, Inc. | 8 | $224 |
| Alkermes, Inc. | 12 | $221 |
| Neos Therapeutics, LP | 5 | $113 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $111 |
| Vanda Pharmaceuticals Inc. | 3 | $84 |
| Bausch Health US, LLC | 4 | $79 |
| Teva Pharmaceuticals USA, Inc. | 2 | $50 |
Products named: VRAYLAR, Auvelity, INGREZZA, ARISTADA, REXULTI, Adzenys XR-ODT, CAPLYTA, ABILIFY ASIMTUFII.
Industry payments across MD — which companies pay providers there.
